Hostname: page-component-7479d7b7d-t6hkb Total loading time: 0 Render date: 2024-07-14T21:38:36.177Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical antipsychotics and the negative symptoms of schizophrenia

Published online by Cambridge University Press:  02 January 2018

David J. King
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The concept of positive and negative symptoms in schizophrenia can be traced back to Hughlings Jackson (1889) who taught that disease does not create, it sets free, and accordingly positive symptoms could be seen as ‘release’ phenomena resulting from ‘dissolution’ of the highest cerebral centres of the nervous system. Crow (1980) revived the dichotomy and proposed a Type I syndrome, characterised by positive symptoms, and a Type II syndrome, characterised by negative symptoms. He thought the latter was due to cortical atrophy and responded poorly to antipsychotic medication. In their review of the distinction, Walker & Lewine (1988) found a stronger relationship between premorbid dysfunction and negative symptoms than with positive symptoms. They also found there was a stronger influence of genetic factors on negative symptoms than positive symptoms.

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 4 , Issue 1 , January 1998 , pp. 53 - 61
Copyright
Copyright © The Royal College of Psychiatrists 1998 

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Andreasen, N. C. (1982) Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry, 39, 784–788.Google Scholar
Andreasen, N. C. (1984) Scale for the Assessment of Positive Symptoms. Iowa City, IA: Department of Psychiatry, University of Iowa.Google Scholar
Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79–91.Google Scholar
Barnas, C., Stuppäck, C. H., Miller, C. et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial versus haloperidol. International Clinical Psychopharmacology, 7, 23–27.Google Scholar
Barnes, T. R. E. (1994) The assessment of negative symptoms. In The Assessment of Psychoses: A Practical Handbook (eds Barnes, T. R. E. & Nelson, H. E.) pp. 51–70. London: Chapman and Hall Medical.Google Scholar
Beasley, C. M., Tollefson, G., Tran, P. et al (1996) Olanzapine versus placebo and haloperidol. Neuropsychopharmacology, 14, 111–123.Google Scholar
Bondolfi, G., Baumann, P., Patris, M. et al (1996) A randomised double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. European Neuropsychopharmacology, 6 (suppl. 2), 21–25.Google Scholar
Boyer, P., Lecrubier, Y., Puech, A. J. et al (1995) Treatment of negative symptoms of schizophrenia with amisulpride. British Journal of Psychiatry, 166, 68–72.CrossRefGoogle ScholarPubMed
Breier, A., Buchanan, R. W., Kirkpatrick, B. et al (1994) Effects of clozapine on positive and negative symptoms in out-patients with schizophrenia. American Journal of Psychiatry, 151, 20–26.Google Scholar
Carpenter, W. T., Heinrich, D. W. & Wagman, A. M. I. (1988) Deficit and non-deficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578–583.Google Scholar
Chouinard, G., Ross-Chouinard, A., Annable, L. et al (1980) The extrapyramidal symptom rating scale. Canadian Journal of Neurological Science, 7, 233.Google Scholar
Chouinard, G., Jones, B., Remington, G. et al (1993) A Canadian multicentre, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25–40.Google Scholar
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–68.Google Scholar
Gerlach, J. & Peacock, L. (1995) New antipsychotics: the present status. International Clinical Psychopharmacology, 10 (suppl. 3), 39–48.Google Scholar
Hale, A., Van der Burgh, M., Friberg, H. H. et al (1996) Dose ranging study comparing four doses of sertindole and one dose of haloperidol in schizophrenic patients. European Neuropsychopharmacology, 6 (suppl. 3), 61.Google Scholar
Harvey, C. A., Curson, D. A., Pantelis, C. et al (1996) Four behavioural syndromes of schizophrenia. British Journal of Psychiatry, 168, 562–570.Google Scholar
Hagger, C., Buckley, P., Kenny, J.-T. et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702–712.CrossRefGoogle ScholarPubMed
Hirsch, S. R., Link, C. G. G., Goldstein, J. M. et al (1996) ICI 204, 636: A new atypical antipsychotic drug. British Journal of Psychiatry, 168 (suppl. 29), 45–56.Google Scholar
Hughlings Jackson, J. (1889) On post-epileptic states: a contribution to the comparative study of insanities. Journal of Mental Science, 34, 490–500.Google Scholar
Hurst, B. C. & Link, C. G. G. (1996) ‘Seroquel’ (ICI 204,636)–efficacy in treating the negative symptoms of schizphrenia. European Neuropsychopharmacology, 6 (suppl. 4), 124.Google Scholar
Jaskiw, G. E. & Weinberger, D. R. (1992) Dopamine and schizophrenia: a cortically corrective perspective. Seminars in the Neurosciences, 4, 179–188.Google Scholar
Kane, J., Honigfeld, G., Singer, J. et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Kay, S. R., Opler, L. A. & Lindenmayer, J. P. (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry, 155 (suppl. 7), 59–67.Google Scholar
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica, 55, 299–308.CrossRefGoogle ScholarPubMed
Liddle, P. (1987) The symptoms of chronic schizophrenia: a reexamination of the positive–negative dichotomy. British Journal of Psychiatry, 151, 145–151.Google Scholar
Lieberman, J. A. (1993) Understanding the mechanism of action of atypical antipsychotic drugs. British Journal of Psychiatry, 163 (suppl. 22), 7–18.Google Scholar
Loo, H., Poirer-Littre, M.-F., Theron, M. et al (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry, 170, 18–22.Google Scholar
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 15, 825–835.Google Scholar
Meilers, J. D. C., Sham, P., Jones, P. B. et al (1996) A factor analytic study of symptoms in acute schizophrenia. Acta Psychiatrica Scandinavica, 93, 92–98.Google Scholar
Möller, H.-J., van Praag, H. M., Aufdembrinke, B. et al (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology, 115, 221–228.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799–812.Google Scholar
Petit, M., Raniwalla, J., Leutenegger, E. et al (1996) A double-blind study of zotepine vs haloperidol in schizophrenia. Psychopharmacology Bulletin, 32, 81–87.Google Scholar
Peuskens, J. on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712–726.Google Scholar
Reeves, K. (1996) The efficacy and safety of two fixed doses of ziprasidone in schizphrenia. European Neuropsychopharmacology, 6 (suppl. 3), 201.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum, 212, 11–19.Google Scholar
Tandon, R., Harrigan, E. & Zorn, S. H. (1997) Zoprasidone: a novel antipsychotic with unique pharmacological and therapeutic potential. Journal of Serotonin Research, 4, 159–177.Google Scholar
Walker, E. & Lewine, R. J. (1988) The positive/negative symptom distinction in schizophrenia: validity and etiological relevance. Schizophrenia Research, 1, 315–328.Google Scholar
Weinberger, D. R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660–670.Google Scholar
Weinberger, D. R., Berman, K. F. & Zec, R. F. (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Archives of General Psychiatry, 43, 114–124.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.